CJC-1295 DAC

CJC-1295 DAC peptide Canada: a synthetic GHRH analog conjugated with a Drug Affinity Complex (DAC) that enables covalent binding to serum albumin, dramatically extending its biological half-life. Available from Maple Research Labs with greater than 98% HPLC-verified purity and batch-specific COA.

Product Specifications

• Alternative Names: CJC-1295 with DAC, DAC:GRF
• Base Peptide: Modified GRF(1-29) with DAC conjugation
• DAC Component: Maleimidopropionic acid-lysine linker
• Purity: >98% (HPLC verified)
• Form: Lyophilized powder
• Quantity: 5mg per vial

CJC-1295 DAC Peptide Canada Research Summary

CJC-1295 with DAC is a modified GHRH analog that incorporates a Drug Affinity Complex (DAC) – a reactive maleimidopropionic acid group attached via a lysine linker. Upon administration in research models, this reactive group forms a covalent bond with serum albumin (specifically Cys34 of albumin), creating a long-lasting peptide-albumin conjugate. The CJC-1295 DAC peptide Canada product represents a pharmacokinetic engineering approach to extending peptide half-life from minutes to days.

The DAC technology was developed by ConjuChem Biotechnologies and represents a broader platform approach to extending biological peptide half-lives through albumin conjugation. CJC-1295 with DAC was among the first GHRH analogs to demonstrate multi-day biological activity from a single administration in preclinical studies.

Mechanism of Action Research

Like CJC-1295 without DAC, the base peptide acts through the GHRH receptor (GHRHR) on pituitary somatotroph cells. However, the albumin-conjugated form produces a fundamentally different pharmacokinetic profile. Rather than the acute pulsatile GH release seen with Modified GRF(1-29), the DAC version produces sustained elevation of GH secretion over an extended period due to the slow release of active peptide from the albumin conjugate.

Published pharmacokinetic studies have characterized the half-life extension achieved through DAC conjugation. In preclinical models, the albumin-bound form demonstrated elimination half-lives measured in days compared to the minutes observed with unconjugated GHRH analogs. This extended exposure results in continuous GHRH receptor stimulation and sustained IGF-1 axis activation.

Research comparing CJC-1295 with and without DAC has examined differences in GH secretion patterns, IGF-1 elevation profiles, and downstream metabolic effects. These comparative studies have been important for understanding the biological consequences of pulsatile versus sustained GHRH receptor activation in the context of somatotroph physiology.

Preclinical Study Summary

CJC-1295 with DAC has been studied in GH axis pharmacology, pharmacokinetic engineering research, and albumin-conjugation technology development. Published studies have characterized its binding kinetics to albumin, the rate of active peptide release, and the resulting GH and IGF-1 response profiles in animal models.

All findings are from preclinical research. No therapeutic claims are made.

References

• Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006 (PubMed)

CJC-1295 DAC Peptide Canada Quality Assurance

Every batch of CJC-1295 DAC peptide Canada from Maple Research Labs undergoes independent third-party HPLC analysis confirming purity exceeding 98%. Each order includes a batch-specific COA with retention time data, purity percentage, and mass spectrometry identity confirmation. The Drug Affinity Complex conjugation integrity is verified through additional analytical protocols on every batch.

Storage and Handling

Store lyophilized at -20C. Reconstituted at 2-8C, use within 30 days. The DAC component is moisture-sensitive; store under desiccation.

Shipping

Ships same-day from our Canadian facility. Temperature-controlled packaging included.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• Ipamorelin vs CJC-1295: GHRP vs GHRH Research
• Ipamorelin vs Tesamorelin: GHS Research Differences
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for CJC-1295 DAC?

CJC-1295 DAC shares the base CAS number 863288-34-0 with the non-DAC variant. The DAC modification adds a Drug Affinity Complex.

What purity does CJC-1295 DAC achieve?

Batch MRL-CDA-0326 tested at 98.3% purity by HPLC at Janoshik Analytical.

How should CJC-1295 DAC be stored?

Lyophilized: -20C. The DAC modification makes this a larger molecule. Handle with standard peptide storage protocols and avoid repeated freeze-thaw cycles.